Belgium-based Agomab will use some of the proceeds to fund a recently-started phase 2 trial of its lead ALK5 inhibitor AGMB-129 for fibrostenosing Crohn’s disease, a severe form that often ...

Results from the STENOVA trial of AGMB-129, a gut-restricted oral small molecule inhibitor of ALK5, are due early next year. Meanwhile, Agomab will also use some of the proceeds for further ...

Angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) are recommended widely as first-line treatments for hypertension in patients with diabetic or nondiabetic ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

Tumor necrosis factor (TNF)-α inhibitors are associated with an increased risk of fungal infections, according to the findings of a systematic review published in Mycoses. Investigators explored ...

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education and School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, China ...

Department of Pharmacy, the Second Affiliated Hospital of Wannan Medical College, Wuhu 241000, China Research Center of Integration of Traditional Chinese and Western Medicine, Wannan Medical College, ...